Resmed’s Growth Potential Highlighted by Promising Trial Results and Future Opportunities

Morgan Stanley analyst David Bailey has maintained their bullish stance on RMD stock, giving a Buy rating today.

David Bailey’s rating is based on a combination of factors that highlight Resmed’s potential for growth. The recent Phase 3 SynAIRgy trial results for Apnimed’s AD109, which targets patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP, show promising outcomes. A significant portion of patients achieved a reduction in apnea-hypopnea index (AHI), particularly those with mild to moderate OSA, indicating a potential market for Resmed’s products.
Furthermore, the anticipation of additional data from ongoing trials and the expected filing with the US FDA in early 2026 suggest future opportunities for Resmed. Despite some concerns about insomnia in a subset of patients, the overall impact on earnings appears modestly positive. With a projected 13% upside to the price target, Bailey sees Resmed as a favorable investment opportunity.

In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $280.00 price target.